Jan. 15, 2021 06:00 UTC PARIS--(BUSINESS WIRE)-- Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced results from new analyses of pivotal Phase III clinical trial data to assess treatment intervals over repeat cycles of Dysport (abobotulinumtoxinA [aboBoNT-A]) in five patient populations. AbobotulinumtoxinA: Evidence for Long Duration of Response from 5 Patient Populations is being shared during the TOXINS 2021 conference, which is taking place virtually between 16-17 January 2020 and is organized by the International Neurotoxin Association.1-28 Ipsen is sharing 26 abstracts during the congress, with data including updates from the recently published surveys into the experience of patients and caregivers, data from the Phase IV ULIS-III trial, and ten abstracts focused on basic science research into neurotoxins.1-27 Spasticity is one of the most common and disabling conditions associated with many neurological conditions in adults and is characterized by velocity-dependent muscle hypertonia. Continue reading →

Sujok has become popular among people suffering from chronic diseases, especially among the poor who cant afford costly hospitals As the world battles the Coronavirus pandemic and other zoonotic diseases that are plaguing humanity, it is vital to keep healthy and boost immunity. Apart from the use of various allopathic drugs and ayurvedic tonics, people are trying out alternative therapies to improve their overall health and immunity. Continue reading →

CLEVELAND Next week, the 1B phase of the COVID-19 vaccine rollout will begin in Ohio and the Cleveland Clinic and University Hospitals have announced plans for how they will be distributed to its patients. Starting Saturday, individuals 80 years and older will be able to sign up and schedule an appointment to receive the vaccine. Ohio has 750 provider locations across the state and about 100,000 vaccines, which will be made available Tuesday, Wednesday and Thursday next week, depending on the delivery date, Ohio Governor Mike DeWine said Thursday Continue reading →

By: Sandy Eller With COVID rates continuing to spike, a pair of communal organizations in Flatbush are joining forces to urge those who test positive for the virus to undergo a treatment with potentially lifesaving benefits that has been approved for emergency usage by the Food and Drug Administration. Flatbush Hatzolah and the Sephardic Community Alliance have been spreading the word about outpatient monoclonal antibody infusions currently available at multiple hospitals in New York, New Jersey and Florida. Continue reading →